Romosozumab

Romosozumab es un fármaco en desarrollo de Amgen. Tiene 17 ensayos clínicos registrados, 2 en marcha; lo más avanzado, fase 3.

AMGN Amgen

Sus ensayos

Para qué	Fase	Estado
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections NCT07811999	Fase 1	Reclutando pacientes
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta NCT05972551	Fase 3	En marcha, sin reclutar
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. NCT06079476	Fase 4	Completado
Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta NCT04545554	Fase 1	Completado
A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis NCT02791516	Fase 3	Completado
ARCH NCT01631214	Fase 3	Completado
BRIDGE NCT02186171	Fase 3	Completado
FRAME NCT01575834	Fase 3	Completado
Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis NCT01992159	Fase 2	Completado
Osteoporosis NCT01833754	Fase 1	Completado
Osteoporosis NCT01588509	Fase 1	Completado
STARTT-Hip NCT01081678	Fase 2	Completado
STARTT NCT00907296	Fase 2	Completado
A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women NCT01101061	Fase 1	Completado
A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass NCT00950950	Fase 1	Completado
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785) NCT01825785	Fase 1	Completado
A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women NCT01059435	Fase 1	Completado

¿Cuándo se esperan resultados? Está en el calendario, para quien tiene cuenta. Crear una cuenta.

Ensayos del registro público de ClinicalTrials.gov; noticias, de los documentos que la empresa presenta ante la SEC. No son recomendaciones de inversión.